Sometimes the most under-hyped sectors are the best places to build very large businesses,” said one venture investor who ...

Global strategic partner in healthcare, Avalere Health, is proud to announce the appointment of Amar Urhekar as its new Chief ...

The agency is due to make a determination on the shortage status of Zepbound by Dec. 19. But another delay could be possible ...

Almac Clinical Technologies is a global provider of Interactive Response Technology (IRT) and expert consultancy for the biopharmaceutical industry, empowering trial sponsors to pro-actively manage ...

While other big pharmas have faltered, Lilly made headway in a Phase 3 trial that could provide a treatment option to replace ...

Analysts slashed their price targets for the Massachusetts biotech after ‘messy’ trial results in alopecia and eczema.

The combined company, which will pair Chroma’s epigenetic editing with Nvelop’s non-viral particles, has raised $75 million ...

Data from Eli Lilly and AstraZeneca could help doctors decide treatment order in chronic lymphocytic leukemia. Elsewhere, ...

The findings add to evidence that the company’s drug, obicetrapib, could change the narrative surrounding a once-abandoned ...

The company now says that, during a recent meeting with the FDA, the two parties agreed on some key elements for an ...

A lengthy treatment process, coupled with weighty risks for recipients to consider, has resulted in plodding adoption of ...

The biotech disclosed Friday plans to terminate a Phase 2 study testing azelaprag with tirzepatide for weight loss following ...